Drug Profile
Research programme: engineered protease therapeutics - Gyre Therapeutics/AstraZeneca
Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Catalyst Biosciences; MedImmune
- Developer Gyre Therapeutics
- Class Enzymes
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 30 Oct 2023 GNI merged with Catalyst Biosciences to form Gyre Therapeutics
- 28 Jun 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Jun 2018 No recent reports of development identified for research development in Inflammation in USA (Parenteral)